Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
The human brain contains multiple regions, as does the spinal cord. There are multiple ways to divide the brain, including by the embryological development of the brain; into three parts: the cerebellum, brainstem, and cerebrum; the evolution of the brain; and cytoarchitecture, as in the case of Brodmann areas. A popular model of the 'triune brain' — comprising the reptilian complex (basal ganglia), the paleomammalian complex (limbic system), and the neomammalian complex (neocortex) — was formerly popular during the 1960s, though is now regarded as a myth. 'Limbic system' and associated terms, however, remain in neuroanatomical use, although some neuroscientists have argued against such use.
=== Muscular disease === A meta-analysis found that creatine treatment increased muscle strength in muscular dystrophies, and potentially improved functional performance. Creatine treatment does not appear to improve muscle strength in people who have metabolic myopathies. High doses of creatine lead to increased muscle pain and an impairment in activities of daily living when taken by people who have McArdle disease.
All 349 members of the Riksdag are elected in the general elections held every four years. All Swedish citizens who turn 18 years old no later than on the day of the election and have at one point been registered residents are eligible to vote. To stand for election, a candidate must be eligible to vote and be nominated by a political party. A minimum of 4% of the national vote is required for a party to enter the Riksdag, alternatively 12% or more within a constituency. Substitutes for each deputy are elected at the same time as each election, so by-elections are rare. In the event of a snap election, the newly elected members merely serve the remainder of the four-year term.
Cardiac MRI is complementary to other imaging techniques, such as echocardiography, cardiac CT, and nuclear medicine. It can be used to assess the structure and the function of the heart. Its applications include assessment of myocardial ischemia and viability, cardiomyopathies, myocarditis, iron overload, vascular diseases, and congenital heart disease.
== Veterinary use == The medication is approved in the United States for the treatment of atopic dermatitis in dogs and cats. Unlike the human form of the medication, the lower doses used in pets mean the drug acts as an immunomodulator and has fewer side effects than in humans. The benefits of using this product include the reduced need for concurrent therapies to bring the condition under control. It is available as an ophthalmic ointment for dogs called Optimmune, manufactured by Intervet, which is part of Merck. It is also available for dogs and cats via an oral solution called Atopica, manufactured by Elanco. It is also used to treat sebaceous adenitis (immune response against the sebaceous glands), pemphigus foliaceus (autoimmune blistering skin disease), Inflammatory bowel disease, perianal fistulas (anal inflammatory disease), and myasthenia gravis (a neuromuscular disease).
Sources: en.wikipedia.org
On his retirement, Mahathir was named a Grand Commander of the Order of the Defender of the Realm, the highest honour in Malaysia, allowing him to adopt the title of "Tun". Under Mahathir's leadership, Malaysia was transformed into an industrialising nation. He pledged to leave politics "completely", rejecting an emeritus role in Abdullah's cabinet. Abdullah immediately made his mark as a quieter and less adversarial premier. With stronger religious credentials than Mahathir, he beat back PAS's surge in the 1999 election and lead the Barisan Nasional in the 2004 election to its biggest win ever, taking 199 of 219 parliamentary seats. On 23 October, Mingguan Malaysia, a Sunday edition of Utusan Malaysia, published an exclusive interview with Mahathir, marking his first since retiring as prime minister. After retiring, Mahathir maintained a busy schedule, engaging in various activities and speaking engagements both locally and internationally. In 2005, Russian president Vladimir Putin visited him at his private residence, where they held a four-hour meeting discussing Malaysia's economic transformation and development strategies. He emphasized the importance of staying active, stating, "Never retire. You have to work. When you work, it will keep you alive." His office at the Perdana Leadership Foundation and residence at the Mines Resort City, as well as expenses for meal allowances, escorts, bodyguards, a medical officer, and a special assistant during overseas trips, are funded by the government under the Member of Parliament (Remuneration) Act 1980 (Act 237).
==== Skunk ==== Skunk refers to cannabis strains that are strong-smelling and have been likened to the smell of the spray from a skunk. These strains of cannabis are believed to have originated during the early 1980s in the United States prior to larger-scale development and popularization by Dutch growers. They are around five times more potent than traditional herbal cannabis. Just as with other strains of cannabis, skunk is commonly grown in controlled indoor environments under specialized grow lights, or in a greenhouse when full outdoor conditions are not suitable; skunk strains are hybrids of Cannabis sativa and Cannabis indica.
G banding Also Giemsa banding or G-banding. A technique used in cytogenetics to produce a visible karyotype by staining the condensed chromosomes with Giemsa stain. The staining produces consistent and identifiable patterns of dark and light "bands" in regions of chromatin, which allows specific chromosomes to be easily distinguished.
They include reverse transcriptase, which is a viral enzyme involved in the infection of cells by retroviruses, and telomerase, which is required for the replication of telomeres. For example, HIV reverse transcriptase is an enzyme for AIDS virus replication. Telomerase is an unusual polymerase because it contains its own RNA template as part of its structure. It synthesizes telomeres at the ends of chromosomes. Telomeres prevent fusion of the ends of neighboring chromosomes and protect chromosome ends from damage. Transcription is carried out by a DNA-dependent RNA polymerase that copies the sequence of a DNA strand into RNA. To begin transcribing a gene, the RNA polymerase binds to a sequence of DNA called a promoter and separates the DNA strands. It then copies the gene sequence into a messenger RNA transcript until it reaches a region of DNA called the terminator, where it halts and detaches from the DNA. As with human DNA-dependent DNA polymerases, RNA polymerase II, the enzyme that transcribes most of the genes in the human genome, operates as part of a large protein complex with multiple regulatory and accessory subunits.
In June 1884, British imperial interests were ignited in the discovery by Jan Gerrit Bantjes of what would prove to be the world's largest deposit of gold ore at an outcrop on a ridge 69 km (43 mi) south of the Boer capital at Pretoria. The ridge was known locally as the "Witwatersrand" (white water ridge, a watershed). A gold rush to the Transvaal brought thousands of British and other prospectors from around the globe and over the border from the Cape Colony, which had been under British control since 1806.
Sources: en.wikipedia.org
Blood Coagulation factor VII with the name of AryoSeven Altebrel with the generic name of Etanercept and original trade name of Enbrel Zytux with the generic name of Rituximab and original trade name of Rituxan َAryoTrust with the generic name of trastuzumab and original name of Herceptin Stivant with the generic name of bevacizumab and original trade name of Avestin AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.
== Other animals == Extensive comparative anatomy work has been done to study the evolution of pancreatic islets across representatives of all major groups of vertebrates and a number of different invertebrates. Islet organs are absent in any invertebrate and primitive chordates (tunicates and lancelets). During the evolution of vertebrates, the cell types secreting peptides related to insulin, somatostatin, glucagon, and PP moved from the brain to the gastrointestinal track mucosa (insulin first in tunicates, all four in lancelets), and then migrated out sequentially to form an islet structure (insulin and somatostatin first in jawless fish, followed by glucagon in jawed cartilaginous fish, few or no PP in lobe-finned bony fish, numerous PP in some ray-finned bony fish, ghrelin detected in catfish). In birds, other peptide-secreting cells such as IGF-1, PYY, and adrenomedullin have been localized in the islets. Notably, American anglerfish pancreas — unlike those of mammals — has islets that are rich in endocrine cells and mostly free of pancreatic exocrine tissue, making them ideal sources of endocrine cells for research. It eventually enabled the isolation of the cDNA for preproglucagon, which contained the sequence for glucagon and two other glucagon-like peptides (GLP-1 and GLP-2).
=== Disorders of carbohydrate transport and metabolism === 271 Disorders of carbohydrate transport and metabolism 271.0 Glycogenosis Von Gierke's disease McArdle's disease Pompe's disease 271.1 Galactosemia 271.2 Hereditary fructose intolerance 271.3 Intestinal disaccharidase deficiencies and disaccharide malabsorption Lactose intolerance Glucose intolerance 271.4 Renal glycosuria 271.8 Other specified disorders of carbohydrate transport and metabolism 271.9 Unspecified disorder of carbohydrate transport and metabolism
Galen believed that the arterial blood was created by venous blood passing from the left ventricle to the right by passing through 'pores' in the interventricular septum, air passed from the lungs via the pulmonary artery to the left side of the heart. As the arterial blood was created 'sooty' vapors were created and passed to the lungs also via the pulmonary artery to be exhaled. In addition, Ibn al-Nafis had an insight into what would become a larger theory of the capillary circulation. He stated that "there must be small communications or pores (manafidh in Arabic) between the pulmonary artery and vein," a prediction that preceded the discovery of the capillary system by more than 400 years. Ibn al-Nafis' theory, however, was confined to blood transit in the lungs and did not extend to the entire body. Finally, William Harvey, a pupil of Hieronymus Fabricius (who had earlier described the valves of the veins without recognizing their function), performed a sequence of experiments, and published Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus in 1628, which "demonstrated that there had to be a direct connection between the venous and arterial systems throughout the body, and not just the lungs. Most importantly, he argued that the beat of the heart produced a continuous circulation of blood through minute connections at the extremities of the body.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.